We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $111M
1-Year Est. Return 74.4%
This Fund
S&P 500
This Quarter Est. Return
-21.35%
1 Year Est. Return
-74.4%
3 Year Est. Return
-95.55%
5 Year Est. Return
-99.44%
10 Year Est. Return
-99.5%
AUM
$2.43B
AUM Growth
-$314M
Cap. Flow
+$224M
Cap. Flow %
9.21%
Top 10 Hldgs %
48.1%
Holding
447
New
130
Increased
120
Reduced
90
Closed
66

Top Buys

Rank Stock Value
1
IWM icon
iShares Russell 2000 ETF
IWM
+$38.8M
2
BIIB icon
Biogen
BIIB
+$26M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$23.3M
4
VTRS icon
Viatris
VTRS
+$21M
5
GBT
Global Blood Therapeutics, Inc.
GBT
+$16.2M

Top Sells

Rank Stock Value
1
TLT icon
iShares 20+ Year Treasury Bond ETF
TLT
+$28.9M
2
MRK icon
Merck
MRK
+$17.9M
3
XOM icon
ExxonMobil
XOM
+$14.8M
4
ZGNX
Zogenix, Inc.
ZGNX
+$13.4M
5
LPCN icon
Lipocine
LPCN
+$7.13M

Sector Composition

Rank Sector Weight
1 Miscellaneous 82.86%
2 Healthcare 14.52%
3 Energy 1.33%
4 Technology 0.46%
5 Materials 0.45%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PLUR icon
126
Pluri
PLUR
$14.4M
$2.68M 0.11%
18,430
-22,341
-55% -$3.88M
MDGN.WS
127
DELISTED
MEDGENICS INC WT PUR COM EXP 03/31/16
MDGN.WS
$2.54M 0.1%
1,453,640
+13,800
+1% +$36.9K
TPST icon
128
Tempest Therapeutics
TPST
$12.5M
$2.53M 0.1%
102
-19
-16% -$1.28M
FEIC
129
CALL
DELISTED
FEI COMPANY
FEIC
$2.48M 0.1%
340
– –
REGN icon
130
PUT
Regeneron Pharmaceuticals
REGN
$79.7B
$2.46M 0.1%
53
-854
-94% -$459K
SGMO
131
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$2.46M 0.1%
435,225
+111,835
+35% +$922K
RVNC
132
CALL
DELISTED
Revance Therapeutics, Inc.
RVNC
$2.42M 0.1%
815
+201
+33% +$6.11K
LPCN icon
133
Lipocine
LPCN
$18.1M
$2.38M 0.1%
11,848
-30,799
-72% -$7.13M
ALXN
134
CALL
DELISTED
Alexion Pharmaceuticals
ALXN
$2.38M 0.1%
+152
New +$27.7K
LJPC
135
DELISTED
La Jolla Pharmaceutical Company
LJPC
$2.36M 0.1%
+85,011
New +$2.68M
RGLS
136
DELISTED
Regulus Therapeutics
RGLS
$2.33M 0.1%
2,971
+99
+3% +$102K
INO icon
137
CALL
Inovio Pharmaceuticals
INO
$120M
$2.29M 0.09%
+330
New +$28.8K
ASXC
138
CALL
DELISTED
Asensus Surgical, Inc.
ASXC
$2.27M 0.09%
+771
New +$28.6K
NVIV
139
CALL
DELISTED
InVivo Therapeutics Holdings Corp
NVIV
– –
0
– –
RDHL
140
Redhill Biopharma
RDHL
$3.5M
$2.24M 0.09%
+174
New +$2.58M
PRTK
141
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$2.22M 0.09%
117,046
+61,433
+110% +$1.53M
RXDX
142
DELISTED
Ignyta, Inc.
RXDX
$2.22M 0.09%
252,974
+88,874
+54% +$1.27M
BCRX icon
143
PUT
BioCryst Pharmaceuticals
BCRX
$2.09B
$2.2M 0.09%
1,929
-1,390
-42% -$18.5K
PBYI icon
144
PUT
Puma Biotechnology
PBYI
$477M
$2.17M 0.09%
288
+5
+2% +$473
CYTK icon
145
CALL
Cytokinetics
CYTK
$9.64B
$2.08M 0.09%
+3,106
New +$21.2K
RPRX
146
PUT
DELISTED
Repros Therapeutics Inc.
RPRX
$2.08M 0.09%
2,793
+84
+3% +$642
MRTX
147
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$2.06M 0.09%
+60,000
New +$1.81M
RPRX
148
CALL
DELISTED
Repros Therapeutics Inc.
RPRX
$2.06M 0.09%
2,777
+500
+22% +$3.82K
BDSI
149
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$2.05M 0.08%
368,641
+272,541
+284% +$2.01M
CEMP
150
DELISTED
Cempra, Inc.
CEMP
$2.04M 0.08%
73,195
-6,358
-8% -$236K
4 5
6
7 8

Similar funds

IWA
Independent Wealth Advisors Cary, North Carolina $111M AUM
BFA
Ballast Financial Advisors West Chester, Pennsylvania $110M AUM
WPWM
Western Pacific Wealth Management Lake Forest, Illinois $111M AUM 26.64% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $111M AUM 205.39% 1-Year Est. Return
ZS
Zenith Solutions Philadelphia, Pennsylvania $110M AUM
KC
Karras Company Roy, Utah $110M AUM
FI
FinArc Investments Norwood, Massachusetts $110M AUM
CIM
Catalyst Investment Management Windham, New Hampshire $110M AUM

Sabby Management's Q3 2015 Portfolio in Review

As of Q3 2015, Sabby Management held 447 positions worth $2.43B, down 11% from $2.74B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Sabby Management deployed $224M of net new capital in Q3 2015, opening 130 new positions and adding to 120 existing holdings. Its largest new stake was iShares Russell 2000 ETF: 327,168 shares worth $35.7M.

By sector, the portfolio is most concentrated in Miscellaneous at 83% of assets, down from 89% a quarter earlier, followed by Healthcare and Energy.

On the sell side, the largest reduction was Lipocine, an estimated $7.13M trimmed.

  • Sabby Management's largest Q3 2015 buy was iShares Russell 2000 ETF: 327,168 shares worth $35.7M.
  • Sabby Management added most to Mobileye N.V. in Q3 2015, an estimated $8.9M increase.
  • Sabby Management's biggest Q3 2015 reduction was Lipocine, cutting an estimated $7.13M.
  • Sabby Management fully exited iShares 20+ Year Treasury Bond ETF in Q3 2015, selling an estimated $28.9M.
  • Sabby Management's ten largest holdings make up 48% of its $2.43B portfolio in Q3 2015.
  • Sabby Management opened 130 new positions and closed 66 in Q3 2015.
  • Sabby Management's portfolio value fell 11% quarter-over-quarter to $2.43B.

Based on Sabby Management's 13F filing for Q3 2015, filed 16 Nov 2015.